Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of a rotavirus immunization program for the United States.
Pediatrics. 1995 Oct; 96(4 Pt 1):609-15.Ped

Abstract

OBJECTIVE

To estimate the economic consequences in the United States of routine childhood immunization of children younger than 1 year of age with a rotavirus (RV) vaccine.

DESIGN

Cost-effectiveness analysis of a national RV immunization program from the perspective of the health care system and the perspective of society. Estimates of disease incidence, medical expenditures, productivity costs, vaccine efficacy, and vaccine coverage rates were derived from published literature and unpublished vaccine trial reports. The impact of changes in estimates of vaccine efficacy and medical costs was determined by sensitivity analysis.

MAIN OUTCOME MEASURES

Incremental cost effectiveness, expressed as savings per case of RV diarrhea prevented.

RESULTS

Given a vaccine efficacy rate of 50% and a vaccine cost of $30 per dose, an RV immunization program would prevent more than 1 million cases of RV diarrhea, 58,000 hospitalizations, and 82 deaths per year. A vaccine program would cost $243 million per year but would yield net savings of $79 million from the perspective of the health care system and $466 million from the perspective of society. The incremental cost effectiveness was a savings of $459 per case prevented from the societal perspective and $78 per case prevented from the health care system perspective. Sensitivity analyses substantiated net savings over a wide range of variables, and cost effectiveness increased with greater vaccine efficacy or decreased vaccine cost.

CONCLUSIONS

Economic and disease reduction benefits would be realized from the use of an RV vaccine that is partially protective against severe RV diarrhea. These findings suggest that immunization with an RV vaccine would be cost effective and cost saving.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Smith JC
Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Haddix AC
No affiliation info available
Teutsch SM
No affiliation info available
Glass RI
No affiliation info available

MeSH

Child, PreschoolCost-Benefit AnalysisDecision Support TechniquesHumansImmunization ProgramsInfantModels, EconomicRotavirus InfectionsTreatment OutcomeUnited States

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7567319

Citation

Smith, J C., et al. "Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United States." Pediatrics, vol. 96, no. 4 Pt 1, 1995, pp. 609-15.
Smith JC, Haddix AC, Teutsch SM, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics. 1995;96(4 Pt 1):609-15.
Smith, J. C., Haddix, A. C., Teutsch, S. M., & Glass, R. I. (1995). Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics, 96(4 Pt 1), 609-15.
Smith JC, et al. Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United States. Pediatrics. 1995;96(4 Pt 1):609-15. PubMed PMID: 7567319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of a rotavirus immunization program for the United States. AU - Smith,J C, AU - Haddix,A C, AU - Teutsch,S M, AU - Glass,R I, PY - 1995/10/1/pubmed PY - 1995/10/1/medline PY - 1995/10/1/entrez SP - 609 EP - 15 JF - Pediatrics JO - Pediatrics VL - 96 IS - 4 Pt 1 N2 - OBJECTIVE: To estimate the economic consequences in the United States of routine childhood immunization of children younger than 1 year of age with a rotavirus (RV) vaccine. DESIGN: Cost-effectiveness analysis of a national RV immunization program from the perspective of the health care system and the perspective of society. Estimates of disease incidence, medical expenditures, productivity costs, vaccine efficacy, and vaccine coverage rates were derived from published literature and unpublished vaccine trial reports. The impact of changes in estimates of vaccine efficacy and medical costs was determined by sensitivity analysis. MAIN OUTCOME MEASURES: Incremental cost effectiveness, expressed as savings per case of RV diarrhea prevented. RESULTS: Given a vaccine efficacy rate of 50% and a vaccine cost of $30 per dose, an RV immunization program would prevent more than 1 million cases of RV diarrhea, 58,000 hospitalizations, and 82 deaths per year. A vaccine program would cost $243 million per year but would yield net savings of $79 million from the perspective of the health care system and $466 million from the perspective of society. The incremental cost effectiveness was a savings of $459 per case prevented from the societal perspective and $78 per case prevented from the health care system perspective. Sensitivity analyses substantiated net savings over a wide range of variables, and cost effectiveness increased with greater vaccine efficacy or decreased vaccine cost. CONCLUSIONS: Economic and disease reduction benefits would be realized from the use of an RV vaccine that is partially protective against severe RV diarrhea. These findings suggest that immunization with an RV vaccine would be cost effective and cost saving. SN - 0031-4005 UR - https://www.unboundmedicine.com/medline/citation/7567319/Cost_effectiveness_analysis_of_a_rotavirus_immunization_program_for_the_United_States_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=7567319 DB - PRIME DP - Unbound Medicine ER -